A Multicentre Randomized Clinical Trial on Efficacy and Safety of Huxin Formula in Patients Undergoing Percutaneous Coronary Intervention

Table 2

Baseline clinical data (𝑛, %).

	Control group (𝑁=316)	Treatment; group (𝑁=324)	𝑃
Age (𝑥±𝑠)	59.67±9.33	60.91±8.97	0.09
Gender
Male	249 (78.8)	250 (77.2)	0.62
Female	67 (21.2)	74 (22.8)
Height (𝑥±𝑠)	166.34+7.14	166.04+7.37	0.60
Weight (𝑥±𝑠)	66.56±8.89	64.82±9.53	0.02
Pulse (𝑥±𝑠)	74.6±11.93	75.56±11.92	0.31
Breath (𝑥±𝑠)	19.52±2.03	19.41±1.69	0.46
Heart rate (𝑥±𝑠)	74.71±12.01	75.75±12.29	0.28
SBP (𝑥±𝑠)	129.17±19.29	130.30±22.00	0.49
DBP (𝑥±𝑠)	77.21±11.44	77.89±12.58	0.47
Combined disease
Dyslipidemia	96 (30.4)	91 (28.1)	0.52
Hypertension	182 (57.6)	179 (55.2)	0.55
Diabetes	72 (22.8)	60 (18.5)	0.18
Stroke	16 (5.1)	13 (4.0)	0.52
Heart failure	10 (3.2)	12 (3.7)	0.71
Gastrointestinal disorder	31 (9.8)	26 (8.0)	0.43
Arrhythmia	18 (5.7)	18 (5.6)	0.94
Medical history
Smoking	159 (50.3)	165 (50.9)	0.88
Drinking	50 (15.8)	52 (16.0)	0.94
Family history of CVD	41 (13.0)	49 (15.1)	0.43
Allergy	31 (9.8)	30 (9.3)	0.81
Clinical classification of CHD
Unstable angina	168 (53.2)	193 (59.6)	0.10
Ml	148 (46.8)	131 (40.4)
Cardiac functions
I	117 (37.0)	122 (37.7)
II	157 (49.7)	166 (51.2)	0.70
III	42 (13.3)	36 (11.1)

CHD: coronary heart disease, CVD: cardiovascular disease, DBP: diastolic blood pressure, MI: myocardial infarction, and SBP: systolic blood pressure.